Stocks Traders Are Watching: April 24, 2017

The market are edging higher after the results of the first round of the French Presidential election. The results came in, and Emmanuel Macron and Marine Le Pen will be advancing to the next stage of the election. Now, pollers got it right this time, but we don’t know whether they’ll be right again at next round in early May 2017. That in mind, there market was expecting this, and it got what it wanted. Enough with politics, the next round is a few weeks away, and we’re focused on today. There are a lot of stocks moving , and here are some stocks traders are watching today.


Ocean Power Technologies Inc (NASDAQ: OPTT) shares are up over 40% during the premarket after the company announced after the close on Friday, that a PB3 PowerBuoy was deployed in Japan, as part of its first lease agreement with Mitsui Engineering and Shipbuilding. The PB3 was first shipped to Japan back in February, and reached Tokyo in March. Thereafter, it had to go through standard customs processing, and it was finally transported to Kozu-shima Island. This was the first time OPT deployed PB3 in Japanese waters and it’s already exceeded 2K Watts of peak power.

Here’s a look at the stock on the daily chart:

Source: TradingView


Sarepta Therapeutics Inc (NASDAQ: SRPT) is up around 5% ahead of the bell, after Barron’s noted that the stock could     more than double. In the article, it gave some reasons behind why the stock could double or more, which would be attributed to the potential that the sales of SRPT’s Exondys 51 would increase in 2017, as well as 2018. Currently, according to the Barron’s article, Exondys is the only FDA-approved drug for Duchenne muscular dystrophy, and SRPT’s treatment aims to slow the progression of the treatment, not cure it.

Look at SRPT’s performance on the daily chart:

stocks traders are watching

Source: TradingView


aTyr Pharma Inc (NASDAQ: LIFE) shares are up over 7% during the premarket, after the company announced top-line results from Resolaris Phase Ib/2 clinical trial. The Phase Ib/2 003 trial assessed the safety and potential activity of Resolaris in patients experiencing early onset facioscapulohumeral muscular dystrophy (FSHD). That in mind, 63% of patients had increased from baseine in their Manual Muscle Test, that is used to measure muscle strength. Moreover, 67% of patients had improvements in their Individualized Neuromuscular Quality of Life score.

Here’s a look at LIFE on the daily chart:

Source: TradingView


Gold Fields Limited (ADR) (NYSE: GFI) shares are down just over 5% after the company was downgraded and weak gold prices after the first round French Presidential election results. Gold futures for delivery in May 2017 were down over 1%. RBC Capital downgraded Gold Fields to Underperform from Sector Perform, after the firm noted that it sees the stock as overvalued.

Here’s a look at GFI during the premarket:

Source: TradingView

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) shares were up over 5% ahead of the bell, after announcing it successfully testing the Flying B Ranch #2 vertical well in Lower Wolfcamp A and Upper Wolfcamp B sections. This well is testing at approximately 20 barrels per day, and the test provided confirmation for the second horizontal bench in the Hazel Project. The next step for the company is to test Flying B Ranch #2 well in the Leonard interval and frac it to prove up a third horizontal bench.

Take a look at TRCH on the daily chart:

Source: TradingView


Please enter your comment!
Please enter your name here